Lymphoma Clinical Trials in Ningbo, Zhejiang
9 recruitingNingbo, Zhejiang, China
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 3
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Non-Hodgkin's LymphomaHematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University99 enrolled17 locationsNCT06520163
Recruiting
Phase 2
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Diffuse Large B Cell Lymphoma
First Affiliated Hospital of Ningbo University30 enrolled1 locationNCT06764017
Recruiting
Phase 2
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy
Diffuse Large B Cell LymphomaDLBCL
First Affiliated Hospital of Ningbo University50 enrolled1 locationNCT06758037
Recruiting
Phase 4
Clinical Study of OR for Second-line Treatment of Refractory MZL
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng39 enrolled3 locationsNCT06134284
Recruiting
Not Applicable
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
Multiple MyelomaLymphoma
The Affiliated People's Hospital of Ningbo University68 enrolled14 locationsNCT05536154
Recruiting
Phase 1Phase 2
A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.107 enrolled25 locationsNCT05959694
Recruiting
Phase 1
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
Diffuse Large B Cell Lymphoma
Ningbo No. 1 Hospital24 enrolled2 locationsNCT05659628
Recruiting
Phase 1
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
LymphomaLeukemiaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University10 enrolled1 locationNCT05528887